A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - Secondary parameter analyses

Pharmacopsychiatry

Volumn 41, Issue 6, 2008, Pages 232-239

  Häßler, Frank ^a   Glaser, T ^b   Pap, A F ^b   Beneke, M ^b   Diefenbacher, A ^c   Reis, O ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b BAYER AG   (Germany)

^c Queen Elisabeth Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM SALT; LORAZEPAM; PLACEBO; ZUCLOPENTHIXOL;

ADULT; AGGRESSION; AKATHISIA; AMENORRHEA; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HEART RATE; HEMATOMA; HUMAN; INFECTION; MALE; MENTAL DEFICIENCY; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE RIGIDITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TORTICOLLIS; TREMOR; VASCULAR DISEASE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CLOPENTHIXOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTELLIGENCE TESTS; MALE; MENTAL RETARDATION; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 58049094747     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082072     Document Type: Article

References (28)

1. Aman MG, Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-1346
2. Ballinger BR, Ballinger CB, Reid AH, MacQueen E. The psychiatric symptoms, diagnoses and care need of 100 mentally handicapped patients. BrJ Psychiatry 1991; 158: 251-254
3. Baumeister AA, Sevin JA, King B. Neuroleptics. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus Ohio State University, Nisonger Center 1998: 133-150
4. Baumeister AA, Todd ME, Sevin JA. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clin Neuropharmacol 1993; 16: 271-294
5. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein DP. Development of neuropharmacologically based behavioural assessments of impulsive aggressive behaviour. J Neuropsychiat Clin Neurosci 1991; 3: 44-55
6. Goedhard LE, Stolker JJ, Nijman HLI, Egberts ACG, Heerdink ER. Aggression of psychiatric patients associated with the use of as-needed medication. Pharmacopsychiatry 2007; 40: 25-29
7. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: U.S. Department of Health, Education and Welfare publication (ADM) 1976; 218-222, 284-285, 300-302
8. Haessler F, Glaser T, Beneke M, Pap AF, Bodenschatz R, Reis O. Zuclopenthixol treatment in adults with learning disabilities showing aggressive behaviours: discontinuation study. Br J Psychiat 2007; 190: 1-2
9. Haessler F. Psychopharmacotherapy in mentally retarded adults. Psychopharmakotherapie 1998; 5: 76-80
10. Holmes N, Shah A, Wing L. The Disability Assessment Schedule: a brief screening device for use with the mentally retarded. Psychol Med 1982: 12: 879-890
11. Honigfeld G, Gillis RD, Klett CJ. NOSIE. Nurse's Observation Scale for Inpatient Evaluation. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology, Revised Ed. Rockville: Maryland 1976; 265-273
12. Izmeth M, Khan SY, Kumarjeewa DI, Shivanathan S, Veall RM, Wiley YV. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Pharmacotherapeutica 1988; 5: 217-227
13. Karsten D, Kivimaeki T, Linna SL. Neuroleptic treatment of oligophrenic patients. Acta Psychiatr Scand 1981; 64 (suppl): 39-45
14. Kay SR, Wolkenfield F, Murril LM. Profiles of aggression among psychiatric patients. J Nerv Ment Dis 1988; 176: 539-546
15. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007; 68 (Suppl 6): 10-13
16. Leuner K, Miiller WE. The complexity of the doparninergic synapses and their modulation by antipsychotics. Pharmacopsychiatry 2006; 39 (Suppl 1): 15-20
17. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiat 2002; 41: 140-147
18. Malt LIF, Nystad R, Bache T, Noren O. Efficacy of zuclopenthixol in comparison to haloperidol in the treatment of mentally retarded with behaviour disorders. Br J Psychiat 1995; 166: 374-377
19. Matson JL, Wilkins J. Comment: Antipsychotic drugs for aggression. Lancet 2008; 371: 9-10
20. MacCracken JT, MacGough J, Shah B, Cronin P, Hong D, Aman MG. Risperidone in children with autism and serious behavioural problems. New Engl J Med 2002; 347: 314-321
21. Meins W, Auwetter J, Krausz M, Turnier Y. Behandlung mit Psychopharamka in unterschiedlichen Einrichtungen für geistig Behinderte [Psychotropic drug treatment in different types of residential care for the mentally retarded]. Der Nervenarzt 1993; 64: 451-455
22. Mikhail AG, King BH. Self-injurious behaviour in mental retardation. Curr Opin Psychiat 2001; 14: 457-461
23. Oliver C, Petty J. Self-injurious behaviour in people with intellectual disability. Curr Opin Psychiatry 2002; 15: 477-481
24. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet 1999; 354: 233-242
25. Singh I, Owino WJ. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped inpatients with associated behavioural problems. J Intellect Disabil Res 1992; 23: 541-549
26. Tyrer P, Oliver-Africana PC, Ahemd Z, Bouras N, Cooray S. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57-63
27. Werry JS. Severe conduct disorder-some key issues. Can J Psychiatry 1997; 42: 577-583
28. Yudofski SC, Silver JM, Jackson W, Endicott J, Williams D. The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143: 35-39